Search Videos by Topic or Participant
Browse by Series:

EGFR Inhibition in RAS Wild-Type Unresectable mCRC

Panelists:Dirk Arnold, MD, PhD, Tumor Biology Center; Fortunato Ciardiello, MD, PhD, Second University of Naples; John L. Marshall, MD, Georgetown University Hospital
Published: Tuesday, Sep 08, 2015

 
Aggressive systemic therapy should be administered for symptomatic patients with unresectable, RAS wild-type metastatic colorectal cancer, states Fortunato Ciardiello, MD, PhD. Possible chemotherapy regimens include FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin). An anti–EGFR monoclonal antibody, either cetuximab or panitumumab, may be used for 3 months if the individual’s disease is RAS wild-type, adds Dirk Arnold, MD, PhD. The efficacy and toxicity is similar between the therapies, says Ciardiello.
 
Anti–EGFR therapy is often continued until a good response is achieved as long as the patient is tolerating the therapy, notes Ciardiello. Current data are insufficient to support treating a patient for many years with anti-EGFR therapy, if there is no disease relapse.

FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab, cetuximab, or panitumumab could be a strategy that offers short and intense cytotoxic treatment for tumor shrinkage. However, FOLFOXIRI should not be given alone for extended periods of time, adds Ciardiello.
 
Slider Left
Slider Right

 
Aggressive systemic therapy should be administered for symptomatic patients with unresectable, RAS wild-type metastatic colorectal cancer, states Fortunato Ciardiello, MD, PhD. Possible chemotherapy regimens include FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin). An anti–EGFR monoclonal antibody, either cetuximab or panitumumab, may be used for 3 months if the individual’s disease is RAS wild-type, adds Dirk Arnold, MD, PhD. The efficacy and toxicity is similar between the therapies, says Ciardiello.
 
Anti–EGFR therapy is often continued until a good response is achieved as long as the patient is tolerating the therapy, notes Ciardiello. Current data are insufficient to support treating a patient for many years with anti-EGFR therapy, if there is no disease relapse.

FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab, cetuximab, or panitumumab could be a strategy that offers short and intense cytotoxic treatment for tumor shrinkage. However, FOLFOXIRI should not be given alone for extended periods of time, adds Ciardiello.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x